The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

24 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
20
Design, Synthesis, and Biological Evaluation of Coupled Bioactive Scaffolds as Potential Anticancer Agents for Dual Targeting of Dihydrofolate Reductase and Thioredoxin Reductase.EBI
National University of Singapore
35
Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy.EBI
Peking University
1
Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.EBI
University of Florence
13
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.EBI
University of Padova
4
Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi.EBI
University of California Santa Cruz
32
Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.EBI
National Human Genome Research Institute
1
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum.EBI
Biochemie-Zentrum Der Universit£T Heidelberg
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.EBI
Johann Wolfgang Goethe University
19
Synthesis, cytotoxicity, antioxidant activity and molecular modeling of new NSAIDs-EBS derivatives.EBI
Jianghan University
12
Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors.EBI
Wannan Medical College
5
Beyond direct Nrf2 activation; reinvestigating 1,2,4-oxadiazole scaffold as a master key unlocking the antioxidant cellular machinery for cancer therapy.EBI
Alexandria University
8
Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: Optimization of potency and evaluation of anticancer potential.EBI
University of Belgrade
5
Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling.EBI
Nantong University
14
Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy.EBI
University of Belgrade
1
Novel curcumin analogue hybrids: Synthesis and anticancer activity.EBI
Anhui Medical University
1
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).EBI
Florida International University
1
Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.EBI
Lanzhou University
22
RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOFBDB
Genetolead
302
Substituted 6-azabenzimidazole compoundsBDB
Gilead Sciences
42
Inhibitors of dihydroceramide desaturase for treating diseaseBDB
Centaurus Therapeutics
44
Substituted Bicyclic Heteroaryl Sulfonamide Derivatives for the Treatment of CancerBDB
Nodus Oncology
150
Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereofBDB
Wigen Biomedicine Technology (Shanghai)
16
BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex.BDB
Boehringer Ingelheim Italia